NATDAC (daclatasvir) / NATCO, Hetero - LARVOL DELTA

In silico screening of potential FGF2 inhibitors for cancer therapy. (PubMed, In Silico Pharmacol) - "Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2."

Journal • Acute Myelogenous Leukemia • Brain Cancer • Breast Cancer • Gastric Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FGF2 • FGFR

Fibrosis Assessment In Patients With Chronic Viral Hepatitis CA/iral Hepatitis B Coinfection Vs. Viral Hepatitis C/Occult Viral Hepatitis B Coinfection: A Monocentric Moroccan (APASL 2025) - "As per HVC, 3 patients received pegylated INF and ribavirin, while 4 patients received sofosbuvir and daclatasvir... This study highlights the need for careful monitoring of patients with HCV and HBV coinfections, particularly those with occult HBV, which is often under-diagnosed and may persist without obvious clinical signs, allowing silent progression of fibrosis. Further research is needed to better understand the underlying mechanisms and optimize treatment strategies for these at-risk populations."

Clinical • Fibrosis • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor

Transformer Based Deep Learning Method Reveals Novel Drugs and Comorbidity Associations in Pulmonary Arterial Hypertension (ATS 2024) - "Drugs with a known PAH association including dasatinib, bosutinib, amfetamines, cyclophosphamide, thiotepa, benfluorex, busulfan, and daclatasvir showed very high probability (> 0...Drugs showing emerging PAH association included other tyrosine kinase inhibitors - ruxolitinib, ponatinib; antimetabolites - cytarabine, fluorouracil, fludarabine; and proteasome inhibitor bortezomib (probability: 0... Transformer-based Deep Learning methods can capture embedded patterns within heterogeneous biomedical data and predict clinical associations in PAH. Our proposed Deep Learning model shows promise to identify established as well as novel PAH associations and reveal potential causal relationships in PAH."

Cardiovascular • Chronic Myeloid Leukemia • Diabetes • Fibrosis • Heart Failure • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Leukemia • Metabolic Disorders • Obesity • Oncology • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Septic Shock • Systemic Sclerosis • Type 2 Diabetes Mellitus

Predictive Potential Of Il28b Gene In Hcv Patients, Resistant To Daclatasvir And Sofosbuvir In KPK Population. (PubMed, J Ayub Med Coll Abbottabad) - "In rs12979860 T/C model, genotype of IL28-B in the responder and resistant group significantly varies at p-value =0.00572. We conclude that in SNP at rs12979860, CC genotype is associated with clearance of HCV, while CT genotype was more prevalent in the resistant group and associated with chronicity."

Journal • Gastroenterology • Hepatitis C • Hepatology • Infectious Disease • Inflammation • IFNL3

HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol. (PubMed, BMC Public Health) - P=N/A | "The HepFREEPak study will provide evidence on the efficacy of available and widely used treatment options in Pakistan. It will also provide data on the incidence rate of primary infections and re-infections. Data on incidence risk factors will allow us to model and incorporate heterogeneity of risk and how that affects screening and treatment strategies. These data will identify any gaps in current test-and-treat programs to achieve HCV elimination in Pakistan."

Journal • Observational data • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation

Cost of Illness (COI) Associated with Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Viral (HCV) Infection in India: A Systematic Literature Review (ISPOR-EU 2023) - "Mean drug cost/patient for 12 weeks with sofosbuvir+velpatasvir was INR43,447±21,247 in private and INR13,183±136 from state-government, with sofosbuvir+daclatasvir INR30,702±17,847 in private and INR4,019±849 from state-government, and with sofosbuvir+ledipasvir INR22,755±9,268 in private setting and INR9,576±0 from state-government...No study for voxilaprevir and its combination was identified... This SLR showed significant difference between market price (private) and state-government price for DAAs. High cost of DAAs is still a hinderance in HCV infection eradication. There was significant heterogeneity in costs among studies, so there is need to conduct more real-world studies on costs associated with HCV infection."

Review • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study. (PubMed, New Microbiol) - "All were treated with DAAs for 12 weeks (5 with Paritaprevir-Ombitasvir-Ritonavir-Dasabuvir, 3 with Sofosbuvir-Ledipasvir, 1 with Sofosbuvir-Ribavirin, 1 with Sofosbuvir-Daclatasvir, 1 with Sofosbuvir-Velpatasvir) and 100% achieved SVR12...Our study shows that viral eradication obtained with DAA is associated with a trend in restoring the heterogeneity of α-diversity and in reducing the percentage of potentially pathogenic microbial species, although this benefit is less evident in patients with cirrhosis. Further studies with larger sample size are needed to confirm these data."

Journal • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis. (PubMed, J Clin Transl Hepatol) - "Patients on SOF/velpatasvir±ribavirin achieved a significantly higher SVR (91.0%, 95% CI: 87.7-93.9) than that of SOF/ledipasvir±ribavirin [(86.3%, 95% CI: 84.6-87.8); p=0.004)], or on SOF/daclatasvir±ribavirin (82.4%, 95% CI: 78.2-86.2%; p<0.001)...There was no publication bias. The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy, with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients."

Journal • Retrospective data • Review • Fibrosis • Gastrointestinal Cancer • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Oncology • Solid Tumor

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. (PubMed, World J Gastroenterol) - "Similar to the observation made in HIV-negative patients, sustained virologic response 12 wk off-therapy with DAAs is high in PLWH coinfected with HCV-6."

Journal • Real-world evidence • Fibrosis • Gastroenterology • Gastrointestinal Cancer • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor • CD4

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. (PubMed, BMC Infect Dis) - "Although select antivirals have exhibited efficacy to improve clinical outcomes in COVID-19 patients, none demonstrated efficacy in reducing mortality. Larger RCTs are needed to conclusively establish efficacy."

Clinical • Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. (PubMed, PLoS Med) - "In this NMA, we found that anti-inflammatory agents (corticosteroids, tocilizumab, anakinra, and IVIG), convalescent plasma, and remdesivir were associated with improved outcomes of hospitalized COVID-19 patients. Hydroxychloroquine did not provide clinical benefits while posing cardiac safety risks when combined with azithromycin, especially in the vulnerable population. Only 29% of current evidence on pharmacological management of COVID-19 is supported by moderate or high certainty and can be translated to practice and policy; the remaining 71% are of low or very low certainty and warrant further studies to establish firm conclusions."

Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

[VIRTUAL] ON-GOING REGISTRY TO UNDERSTAND PATIENT CHARACTERISTICS AND TREATMENT OUTCOMES IN ADULTS WITH CHRONIC HEPATITIS C INFECTION ACROSS ASIA AND AFRICA (AASLD 2020) - "The most common regimen that was used was Daclatasvir/Sofosbuvir followed by Ledipasvir/Sofosbuvir... In this on-going registry of patients with Chronic HCV, sofosbuvir based regimens were effective in the heterogeneous, highly admixed populations across Asia and Africa. Policies should encourage treatment for all Chronic HCV infected patients with sofosbuvir based regimens in Asia and Africa."

Clinical • Hepatitis C Virus • Hepatology • Infectious Disease

Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. (PubMed, Ann Hepatol) - "SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries."

Clinical • Journal • Real-World Evidence • Fibrosis • Hepatitis C Virus • Hepatology • Immunology • Infectious Disease

Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. (PubMed, Hepatology) - "The lower rates of SVR in patients infected with subtype 4r are related to the frequent preexistence at treatment baseline and subsequent selection by DAA treatment of both NS5A and NS5B S282 RASs. Our study suggests that these patients should be identified and receive a triple DAA combination regimen as first-line treatment."

Clinical • Journal • Hepatitis C Virus • Immunology

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. (PubMed, J Hepatol) - "Overall, SVR was lower in HCC compared to non-HCC patients, especially in those with active HCC though heterogeneity was high. Continued efforts are needed to aggressively screen, diagnose and treat HCC to ensure higher CHC cure rates."

Journal • Retrospective data • Review

Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] (clinicaltrials.gov) - P2/3; N=150; Completed; Sponsor: Johns Hopkins Bloomberg School of Public Health; Recruiting ➔ Completed

Combination therapy • Trial completion